|
|
|
|
|
|
|
12.03.26 - 12:03
|
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update (Business Wire)
|
|
|
- PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity -
- Strong Phase 1 ELIMINATE-B trial execution for PBGENE-HBV with 13 patients now dosed across first 5 cohorts; Data updates expected at medical conferences throughout 2026 -
- Received IND Clearance for PBGENE-DMD enabling IRB and site activation for Phase 1/2 FUNCTION-DMD trial; Data from multiple patients expected by year-end 2026 -
- Raised $75 Million in November 2025 extending expected cash runway through multiple clinical inflection points between 2026 and the end of 2028 -DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced financial results for the fourth quarter and fiscal year ended December 31, 2025, and provided a business update.
?...
|
|
|
|
|
09.03.26 - 21:21
|
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026 (Business Wire)
|
|
|
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the fourth quarter 2025 and provide a business update on March 12, 2026.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other gene editing technologies in the way it cuts, its smaller size, and its simpler structure. These features are intended for ARCUS nucleases to drive more defined therapeutic outcomes. Using ARCUS, the Company's pipeline is comprised of clinical stage in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more informati...
|
|
|
|
|
02.03.26 - 13:06
|
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis (Business Wire)
|
|
|
– Milestone payments include $5.25 million cash and $2.25 million purchase of Precision stock–
– Cash received supports Precision's expected cash runway through 2028 and strategic focus on in vivo gene editing pipeline –DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the achievement of a clinical milestone under its license agreement with TG Therapeutics, Inc. (Nasdaq: TGTX). The milestone payment for azercabtagene zapreleucel (azer-cel) was triggered by progress of a Phase 1 clinical trial of azer-cel in progressive forms of multiple sclerosis (MS). As a result of this milestone event, Precision will receive $7.5 million in proceeds, inclusive of $5.25 million cash and $2.25 million for the purchase of 201,504 shares of Precision common stock by TG Therapeutics at $11.17 per share, pursuant to the...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
29.12.25 - 10:45
|
Precision BioSciences: Sind das jetzt Super-Schnäppchen? (Sharedeals)
|
|
|
Die Aktie von Precision BioSciences ist eines der wenigen Biotech-Papiere, die in diesem Jahr keinen Höhenflug erlebten. Im Gegenteil: Die Aktie hat ohne schlechte Unternehmensnews in den letzten Monaten deutlich verloren und notiert aktuell weit unter ihrem Cashwert. Lauert hier ein Super-Schnäppchen? Geneditierung als strategische Grundlage des Unternehmens Precision BioSciences entwickelt Gentherapien auf Basis der […]
The post Precision BioSciences: Sind das jetzt Super-Schnäppchen? first appeared on sharedeals.de....
|
|
|
|
|
|
|
|
|
|
|
11.11.25 - 00:15
|
Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants (Business Wire)
|
|
|
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has agreed to sell by way of an underwritten offering 10,815,000 shares of its common stock and accompanying warrants to purchase up to 5,407,500 shares of common stock at a combined price of $6.14 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 1,400,000 shares of its common stock and accompanying one-half of a warrant to purchase up to 700,000 shares of common stock at a combined price of $6.139995, which represents the per share offering price for the shares of common stock less the $0.000005 per share exercise price for each pre-funded warrant. The gross proceeds to Precision from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected t...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
